The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.
作者： C. Waldherr , M. Pless , H.R. Maecke , A. Haldemann , J. Mueller-Brand
关键词: Octreotide 、 Palliative care 、 Neuroendocrine tumors 、 Progressive disease 、 Cancer pain 、 Surgery 、 Radionuclide therapy 、 Gastroenterology 、 Malignant Carcinoid Syndrome 、 Internal medicine 、 Medicine 、 Median follow-up
摘要: … Endogenous somatostatin (SRIF: somatotropin release inhibiting … In this study the maximum tolerated dose was 6000 MBq/m2. … have to deal with considerable side effects [16, 18-20]. …
annalsofoncology.org
oup.com
oxfordjournals.org
paperity.org参考文章(20)
Kjell Öberg, Advances in chemotherapy and biotherapy of endocrine tumors Current Opinion in Oncology. ,vol. 10, pp. 58- 66 ,(1998) , 10.1097/00001622-199801000-00010
S. Faiss, H. Scherübl, E. O. Riecken, B. Wiedenmann, Drug Therapy in Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic System Recent results in cancer research. ,vol. 142, pp. 193- 207 ,(1996) , 10.1007/978-3-642-80035-1_12
Prinz Ra, Dorsch Tr, Lawrence Am, Clinical aspects of glucagon-producing islet cell tumors. The American Journal of Gastroenterology. ,vol. 76, pp. 125- 131 ,(1981)
A. Otte, E. Jermann, M. Behe, M. Goetze, H. C. Bucher, H. W. Roser, A. Heppeler, J. Mueller-Brand, H. R. Maecke, DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 24, pp. 792- 795 ,(1997) , 10.1007/BF00879669
Jerome M. Feldman, Carcinoid tumors and the carcinoid syndrome. Current Problems in Surgery. ,vol. 26, pp. 835- 885 ,(1989) , 10.1016/0011-3840(89)90010-5
V Johanson, L E Tisell, L Olbe, B Wängberg, O Nilsson, H Ahlman, Comparison of survival between malignant neuroendocrine tumours of midgut and pancreatic origin. British Journal of Cancer. ,vol. 80, pp. 1259- 1261 ,(1999) , 10.1038/SJ.BJC.6690494
Marta Cremonesi, Mahila Ferrari, Stefania Zoboli, Marco Chinol, Michael G. Stabin, Franco Orsi, Helmut R. Maecke, Eduard Jermann, Christopher Robertson, Maurizio Fiorenza, Giampiero Tosi, Giovanni Paganelli, Biokinetics and dosimetry in patients administered with 111In-DOTA-Tyr3-octreotide: Implications for internal radiotherapy with 90Y-DOTATOC European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 26, pp. 877- 886 ,(1999) , 10.1007/S002590050462
George A. Higgins, Lillian Recant, A.Betty Fischman, The glucagonoma syndrome: Surgically curable diabetes American Journal of Surgery. ,vol. 137, pp. 142- 148 ,(1979) , 10.1016/0002-9610(79)90025-4
A. Otte, R. Herrmann, A. Heppeler, M. Behe, E. Jermann, P. Powell, H. R. Maecke, J. Muller, Yttrium-90 DOTATOC: first clinical results. European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 26, pp. 1439- 1447 ,(1999) , 10.1007/S002590050476
E Mitry, E Baudin, M Ducreux, J-C Sabourin, P Rufié, T Aparicio, P Lasser, D Elias, P Duvillard, M Schlumberger, P Rougier, Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin British Journal of Cancer. ,vol. 81, pp. 1351- 1355 ,(1999) , 10.1038/SJ.BJC.6690325